Relay Therapeutics, Inc.
RLAY
Rank in Stocks
#4060
Relay Therapeutics, Inc. is a precision medicine company currently engaged in... Relay Therapeutics, Inc. is a precision medicine company currently engaged in clinical trials. Its central mission involves revolutionizing the drug discovery process, with a particular focus on enhancing the creation of small molecule therapies for specific types of cancer and genetic conditions. The company's pipeline features several promising drug candidates: RLY-4008, an orally administered small molecule designed to inhibit fibroblast growth factor receptor 2 (FGFR2), which is undergoing its initial human trials for patients with advanced or metastatic solid tumors exhibiting FGFR2 alterations; RLY-2608, a leading program targeting mutant phosphoinositide 3 kinase alpha (PI3Ka); and RLY-1971, another oral small molecule, an inhibitor of SHP2 (protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2), currently in Phase 1 trials for individuals with advanced solid tumors. Relay Therapeutics has established strategic partnerships, including a collaboration with D. E. Shaw Research, LLC, which utilizes computational modeling to analyze protein motion for the identification and development of therapeutic compounds. Furthermore, an agreement with Genentech, Inc. supports the development and commercialization of RLY-1971. Founded in 2015 as Allostery, Inc., the company rebranded to Relay Therapeutics, Inc. in December of that year and maintains its headquarters in Cambridge, Massachusetts.
Share Price
$18.35
Market Cap
$4.02B
Change (1 day)
-0.55%
Change (1 year)
160.64%
Country
US
Trade Relay Therapeutics, Inc. (RLAY)
Category
Healthcare
Stock price history for Relay Therapeutics, Inc. (RLAY)
Highest end of day price: $17.91 on 2026-10-01
Lowest end of day price: $37.16 on 2020-07-01
Lowest end of day price: $37.16 on 2020-07-01
Stock price history of Relay Therapeutics, Inc. from 2020 to 2026
Annual Stock Price Performance
| Year | Performance |
|---|---|
| 2026 (TTM) | 61.51% |
| 2025 | 81.45% |
| 2024 | -55.68% |
| 2023 | -38.67% |
| 2022 | -45.02% |
| 2021 | -37.95% |
| 2020 | 0.00% |
Stock price for similar companies or competitors
| Company | Stock price | Change 1y% | Country |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
